Clinical Report: Cleansing with Antiseptics to Mitigate Pathogen Transmission to Newborns
Overview
The NeoVT-AMR trial evaluated the effectiveness of various antiseptic regimens to reduce bacterial load in laboring women and neonates. Results indicated that 1% chlorhexidine applied to both mothers and newborns significantly lowered bacterial load compared to standard care, with no safety concerns identified. The trial utilized a factorial design with separate allocations for mothers and neonates.
Background
Neonatal infections are a leading cause of mortality, particularly in low-income countries, where serious bacterial infections, including those caused by Klebsiella species and Escherichia coli, account for approximately 680,000 deaths annually. Antiseptic cleansing during labor may offer a cost-effective strategy to reduce the risk of early-onset sepsis in newborns. The NeoVT-AMR trial aimed to explore the efficacy of different antiseptic agents in mitigating pathogen transmission from mothers to their infants.
Data Highlights
Intervention
Effect on Bacterial Load
1% Chlorhexidine
Significantly reduced bacterial load
2% Chlorhexidine
Less effective than 1%
OHP (Octenidine 0.1% with Phenoxyethanol 2%)
Comparative effectiveness not established; further research needed.
Key Findings
1% chlorhexidine was the most effective antiseptic for reducing bacterial load.
Multiple applications of antiseptics to neonates showed increasing benefits over time.
No safety signals were reported during the trial.
The trial included a factorial design with 6 intervention arms and a standard of care arm, allowing for comprehensive comparisons.
Results support the need for larger pragmatic trials to confirm findings in diverse settings.
Clinical Implications
The findings suggest that 1% chlorhexidine could be a viable option for reducing neonatal sepsis risk in low-income settings. Clinicians should consider the use of antiseptic cleansing during labor as part of infection prevention strategies, particularly in high-risk populations, including those with a history of infections.
Conclusion
The NeoVT-AMR trial provides promising evidence for the use of topical antiseptics in reducing bacterial load in laboring women and their newborns, warranting further investigation in larger trials to confirm efficacy and inform clinical practice.
by Emily Beales, Michelle N. Clements, Nicholas A. Feasey, David Lissauer, Maranatha Banda, Bertha Maseko, Julia A. Bielicki, Samantha Lissauer, Aisleen Bennett, Kondwani Kawaza, Luis A. Gadama, A. Sarah Walker, Mike Sharland, Louise F. Hill
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
Interviews with hospital leaders and employed physicians highlighted financial pressures, perceived care-integration benefits, and unresolved operational tensions following acquisition.
